Clinical Trial Update: Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating sorafenib with concurrent hepatic arterial infusion chemotherapy for hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED